학술논문
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Document Type
Article
Author
Cremer, P.C.; Sheng, C.C.; Wang, Q.; Wolski, K.E.; Rajendram, P.; Duggal, A.; Abbate, A.; Van Tassell, B.; Bonaventura, A.; Vecchié, A.; Hudock, K.; Carey, B.; Trapnell, B.C.; McWilliams, C.; Mehta, J.; Chang, S.Y.; Wang, T.S.; Paolini, J.F.; Gladish, D.; Myers, K.; Kuramochi, Y.; Sewell, C.; Balog, C.; Kosty Sweeny, D.; Kandrac, J.; Spencer, S.; Goyanes, A.; Sahoo, D.; Dugar, S.; Aguillon Prada, R.; Nichols, D.; Celiberti, J.; Partisano, A.; Fang, F.; Coehlo, J.; Perrin, R.; Mandell, B.; Gordon, S.; Wiedemann, H.; Young, J.; Greer, J.; Ho, A.-C.; Ladd, A.; Mihalick, V.; Montpetit, A.; O'Brine, J.; Owen, C.; Pal, M.; Priday, A.; Raj Sedhai, Y.; Wohlford, G.; Hummel, N.; Korbee, L.
Source
In: The Lancet Rheumatology . (The Lancet Rheumatology, June 2021, 3(6):e410-e418)
Subject
Language
English
ISSN
26659913